Articles on this Page
- 11/28/18--01:58: _$30+ Billion Genoty...
- 11/28/18--02:07: _An 'alarm bell': Ex...
- 11/28/18--23:46: _Victory over Liverp...
- 11/28/18--23:42: _Biocartis partners ...
- 11/28/18--23:39: _Nexans announces a ...
- 11/28/18--23:55: _Russian gas pipelin...
- 11/28/18--23:51: _Swift Operations Fo...
- 11/29/18--00:00: _Chi-Med Enters into...
- 11/29/18--00:10: _Acron’s IFRS EBITDA...
- 11/29/18--00:08: _Savannah Resources ...
- 11/29/18--00:29: _"Perfect", "Will pu...
- 11/29/18--00:20: _Net Asset Value(s)
- 11/29/18--00:30: _European Road Freig...
- 11/29/18--00:34: _How Celtic can qual...
- 11/29/18--01:01: _Jumio Named to Pres...
- 11/29/18--01:24: _Austerity has measu...
- 11/29/18--01:10: _Local utilities in ...
- 11/29/18--01:13: _US: Crack in financ...
- 11/29/18--01:39: _Aspo's Telko Ltd ha...
- 11/29/18--02:02: _Ford Europe boss sa...
- 11/28/18--01:58: $30+ Billion Genotyping Assay Market 2018 - Global Forecast to 2023
- 11/28/18--23:42: Biocartis partners with AstraZeneca on lung cancer diagnostics
- 11/28/18--23:55: Russian gas pipeline and Ukraine crisis are separate issues: Germany
- 11/28/18--23:51: Swift Operations Forum Europe 2018, Amsterdam - Day 1 report
- 11/29/18--00:08: Savannah Resources PLC: Mina do Barroso Lithium Project Team Expands
- 11/29/18--00:20: Net Asset Value(s)
- 11/29/18--01:10: Local utilities in the energy transition
- 11/29/18--01:13: US: Crack in financial conditions? - AmpGFX
- 11/29/18--02:02: Ford Europe boss says no deal Brexit would be a "catastrophe"
Dublin, Nov. 28, 2018 (GLOBE NEWSWIRE) -- The "Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023" report has been added to *ResearchAndMarkets.com's* offering.
The genotyping market is expected to reach USD 31.9 billion by 2023 from an estimated USD 11.8 billion in 2018, at a CAGR of 22.0%
Technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases are expected to drive the growth of the global genotyping market. However, the high cost of equipment is expected to restrain market growth to a certain extent during the forecast period.*Pharmacogenomics application segment to witness the highest growth during the forecast period.*
On the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostic & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment is expected to register the highest CAGR during the forecast period. The increased use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs are the major factors driving the growth of this market segment.
*Pharmaceutical and biopharmaceutical companies end-user segment is expected to grow at the highest CAGR during the forecast period.*
On the basis of end user, the genotyping market is segmented into pharmaceutical & biopharmaceutical companies, diagnostic & research institutes, academic institutes, and other end users. The pharmaceutical & biopharmaceutical companies segment is expected to witness the highest CAGR owing to the growing importance of biomarkers in genotyping used among these end users, given their applications in drug development which, in turn, will support the growth of this segment.
*APAC is projected to witness the highest growth during the forecast period.*
North America is expected to account for the largest share of the global genotyping market in 2018. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing incidence of chronic diseases and growing awareness on the use of genotyping tests to control the inheritance of genetic diseases & the spread of infectious and microbial diseases in APAC countries.The increasing outsourcing of clinical research and trials by pharmaceutical and biopharmaceutical companies to organizations in the APAC has driven the demand for genotyping products for drug profile assessment, drug efficacy, safety assessment, dosing determination, and drug response evaluation.*Key Topics Covered:**1 Introduction*
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
*2 Research Methodology*
2.1 Research Data
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
*3 Executive Summary*
*4 Premium Insights*
4.1 Genotyping Market Overview
4.2 Asia Pacific: Genotyping Market, By Product & Service, By Country, 2017
4.3 Geographic Snapshot of the Genotyping Market
4.4 Geographic Mix: Genotyping Market
4.5 Genotyping Market: Developing vs Developed Markets
*5 Market Overview*
5.2 Market Dynamics: Impact Analysis
5.3 Market Drivers
5.3.1 Technological Advancements and Decreasing Prices of Dna Sequencing
5.3.2 Increasing Incidence of Genetic Diseases and Rising Awareness on Personalized Medicine
5.3.3 Growing Importance of Genotyping in Drug Development
5.3.4 Increasing Demand for Bioinformatics Solutions in Data Analysis
5.4 Market Restraints
5.4.1 High Cost of Equipment Used in Genotyping
5.5 Market Opportunities
5.5.1 Growing Importance of Sequencing Projects
5.5.2 Increasing Application Areas of Genotyping
5.5.3 Increasing Demand for Genome Analysis in Plant and Animal Livestock
5.6 Market Challenges
5.6.1 Data Management in Genotyping Research
5.6.2 Dearth of Trained Resources
*6 Industry Insights*
6.1 Industry Trends
6.1.1 Increasing Demand for Genotyping & Sequencing Services
6.1.2 Increasing Collaborations
6.1.3 Increasing Awareness
6.2 Regulatory Analysis
6.3 Strategic Benchmarking
6.3.1 Genotyping Market: Product Portfolio Analysis (Instruments & Kits)
6.3.2 Genotyping Market: Product Portfolio Analysis (Bioinformatics)
*7 Genotyping Market, By Product & Service*
7.2 Reagents & Kits
7.2.1 Reagents & Kits Accounted for the Largest Share of the Genotyping Market in 2017
7.3 Genotyping Services
7.3.1 Increasing Demand for Sequencing and Genotyping Services From Hospitals, Small- and Medium-Sized Research Centers, and Pharmaceutical Companies to Drive the Growth of This Segment
7.4.1 Sequencers & Amplifiers
22.214.171.124 Sequencers & Amplifiers Segment to Register the Highest Growth Rate in the Genotyping Instruments Market During the Forecast Period
126.96.36.199 Growing Automation and Advancements in Analyzers With High-Throughput Capacities are the Major Factors Driving Market Growth
188.8.131.52 Software Segment Accounted for the Largest Share of the Genotyping Bioinformatics Market in 2017
184.108.40.206 Shortage of Skilled Bioinformatics Professionals and the Growing Applications of Bioinformatics in Various Industries are the Major Factors Driving the Growth of This Segment
*8 Genotyping Market, By Technology*
8.2 Polymerase Chain Reaction
8.2.1 Real-Time PCR
220.127.116.11 Real-Time PCR Dominated the PCR Market in 2017, Primarily Due to the Growing Adoption of These Instruments Among Researchers and Healthcare Professionals
8.2.2 Digital PCR
18.104.22.168 The High Cost of Dpcr Instruments to Restrain the Growth of This Market
8.3.1 Increasing Demand for Personalized Medicine and Continuous Launch of Custom Arrays By Leading Players to Drive Market Growth
8.4.1 Next-Generation Sequencing
22.214.171.124 NGS to Witness the Highest Growth Rate in the Sequencing Market During the Forecast Period
126.96.36.199 Growing Demand for Pyrosequencing By Pharmaceutical and Biotechnology Companies to Drive the Adoption of This Technology Segment
8.4.3 Sanger Sequencing
188.8.131.52 Increasing Use of This Technology in Small-Scale Experiments is the Major Factor Driving Market Growth
8.5 Capillary Electrophoresis
8.5.1 Amplified Fragment Length Polymorphism
184.108.40.206 Aflp Technique to Witness the Highest Growth Rate in the Capillary Electrophoresis Market During the Forecast Period
8.5.2 Restriction Fragment Length Polymorphism
220.127.116.11 Increasing Demand for Rflp From Forensics, Agricultural Institutions, and Pharmaceutical and Biotechnology Companies-Major Factor Driving Market Growth
8.5.3 Single-Strand Conformation Polymorphism
18.104.22.168 Increasing Applications of Sscp in Virology are Expected to Play A Key Role in the Growth of the Sscp Market
8.6 Matrix-Assisted Laser Desorption/Ionization-Time of Flight (Maldi-Tof) Mass Spectrometry
8.6.1 Increasing Applications of This Technique in Clinical Diagnostics and Pharmacogenomics to Drive Market Growth
8.7 Other Technologies
*9 Genotyping Market, By Application*
9.2.1 Pharmacogenomics Segment Accounted for the Largest Share of the Genotyping Market in 2017
9.3 Diagnostics & Personalized Medicine
9.3.1 Technological Advancements and Increasing Potential of Developing Diagnostics Tests Through Rapid Genotyping Techniques are the Key Factors Driving the Growth of This Application Segment
9.4 Animal Genetics
9.4.1 Lower Adoption of Genotyping Technologies in Animal Breeding Programs in Developing Countries to Restrain the Growth of This Segment
9.5 Agricultural Biotechnology
9.5.1 Increasing Number of Research Laboratories and Greenhouses Using Plant Genotyping and Continuous Product Innovations and New Product Launches are Driving the Growth of the Agricultural Biotechnology Segment
9.6 Other Applications
*10 Genotyping Market, By End User*
10.2 Pharmaceutical & Biopharmaceutical Companies
10.2.1 Pharmaceutical & Biopharmaceutical Companies to Register the Highest Growth During the Forecast Period
10.3 Diagnostic & Research Laboratories
10.3.1 Growing Preference for Personalized Medicine and Increasing Research Focused on Personalized Diagnosis are the Key Factors Driving Market Growth
10.4 Academic Institutes
10.4.1 Increasing Research Activities for Drug Discovery and Rising Industry-Academia Collaborations for Drug Development are the Key Factors Driving Market Growth
10.5 Other End Users
*11 Genotyping Market, By Region*
11.2 North America
22.214.171.124 US Dominated the North American Genotyping Market in 2018; This Trend to Continue During the Forecast Period
126.96.36.199 Increasing Incidence of Genetic Diseases & the Availability of A Wide Range of Genotyping Products to Drive Market Growth in Canada
188.8.131.52 Germany Accounted for the Largest Share of the European Genotyping Market in 2017
184.108.40.206 Increasing Incidence of Genetic Disorders & Growing Public-Private Investments are Driving the Growth of the Genotyping Market in France
220.127.116.11 UK to Witness the Highest Growth in the European Genotyping Market During the Forecast Period
18.104.22.168 Presence of A Well-Developed Healthcare System and Rapid Growth in the Geriatric Population are Key Factors Driving Market Growth in Italy
22.214.171.124 The Lingering Effect of Economic Downturns Will Continue to Affect Healthcare in Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
126.96.36.199 Infrastructural Improvements in China's Healthcare System Have Boosted Treatment Rates and Care Delivery
188.8.131.52 Strong Base of Pharmaceutical Activity Will Contribute to the Use of Genotyping
184.108.40.206 Growth of the Pharmaceutical Industry has Highlighted the Need for Better Infrastructure in India
11.4.4 Rest of APAC
11.5 Latin America
11.6 Middle East and Africa
*12 Competitive Landscape*
12.2 Product Portfolio Matrix
12.3 Market Share Analysis
12.4 Competitive Situations and Trends
*13 Company Profiles*
13.1 Illumina, Inc.
13.2 Thermo Fisher Scientific, Inc.
13.3 Roche Diagnostics Limited
13.4 Qiagen N.V.
13.5 Danaher Corporation
13.6 Agilent Technologies, Inc.
13.7 Fluidigm Corporation
13.8 GE Healthcare
13.9 Genewiz, Inc.
13.10 Integrated Dna Technologies, Inc. (A Subsidiary of Danaher Corporation)
13.11 Perkinelmer, Inc.
13.12 Bio-Rad Laboratories, Inc.
13.13 Eurofins Scientific
13.14 Pacific Biosciences of California, Inc.For more information about this report visit https://www.researchandmarkets.com/research/dxzrrz/30_billion?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics Reported by GlobeNewswire 21 minutes ago.
Reported by Telegraph.co.uk 11 minutes ago.
Tuchel managed to do something on Wednesday night that his predecessors failed to achieve all too often, and this could finally be the year that the penny has dropped for PSG in Europe
Reported by Independent 3 hours ago.
Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.
Reported by Reuters India 3 hours ago.
*Nexans announces a new management team to drive its new industrial project and build future successes*
· Following the presentation of the Group's strategic roadmap on November 9^th 2018, Nexans creates and appoints an Executive Committee of 12 people replacing the two previous governance bodies: the Management Board and the Management Council which were composed of 22 members.
· The new Executive Committee will reflect the strategic importance of the Group's relationship with its customers, its markets and its ability to transform.
· The Executive team will focus on improving the Group's competitiveness through constant cost discipline, ensuring sustainable and profitable growth through strategic resource allocation, and implementing a recovery plan for underperforming activities.
*Paris La Défense, November 29, 2018* - Following the new strategic roadmap announced on November 9^th 2018, Nexans has appointed a new Executive Committee to achieve its objectives, increase the performance of each division and drive the Group's transformation. With its simplified and more agile structure, the Executive Committee, acting as the Group's main governance body, replaces the former Management Board and Management Council.
The Executive Committee will focus on:
· *Increasing proximity with the Group's markets and customers*;
· *Developing* better anticipation and improving the organization's agility;
· *Strengthening the emphasis on execution* - cost control, innovation, development of services and transformation;
· *Reinforcing* Nexans' management with international profiles to better understand and adapt to the changes in the world.
The new Group Executive Committee comprises eleven members gathered around
Christopher Guérin, Chief Executive Officer:
· *Five Executive VPs in charge of geographic areas and business groups*
· *Benjamin Fitoussi*, 46, Senior Executive Vice President & Chief Operations Officer, continues to supervise the Europe area and the Power Accessories Business Group. In addition, he will supervise the Harnesses business of the Automotive segment, as well as the Industrial Operations and Purchasing departments. Benjamin Fitoussi is French, based in Paris. He joined Nexans in 2011 as Strategy and Transformation Director before being appointed, in 2014, Executive Vice President for Middle East, Russia and Africa and Executive Vice President for Resources & Transport Infrastructure. In 2017, he also took the lead of the Industry Solutions and Projects business.
· *Vincent Dessale*, 52, Senior Executive Vice President, remains in charge of the Subsea & Land Systems Business Group. He is French, based in Oslo, Norway. Vincent Dessale joined Nexans in 2001. He held various key positions in Supply Chain in Europe before heading Operations in South Korea in 2006, extending his responsibilities to the Asia-Pacific area in 2009. He held several positions in Submarine High Voltage Business since 2012 before being appointed to his current position in February 2018.
· *Julien Hueber*, 48, is appointed Executive Vice President in charge of the Industry Solutions & Projects Business Group and continues to lead the Asia-Pacific region. Julien Hueber is French, based in Shanghai, China. Julien Hueber joined Nexans in 2002. He has a strong background in Supply Chain and Purchasing, and an excellent knowledge of the Asia-Pacific region where he held various responsibilities in Australia, South Korea and China.
· *Vijay Mahadevan*, 52, is appointed Executive Vice President Middle East, Russia, Africa and South America. He is from India and is based in Paris. Prior to joining Nexans in December 2017, Vijay Mahadevan held the position of CEO of ArcelorMittal Ostrava in the Czech Republic. He spent most of his career in the steel industry at ArcelorMittal, where he held various responsibilities across the globe, including in sales and marketing, plant management and general management. He has extensive knowledge of Eastern Europe, Central Asia, the United States and the Middle East.
· *Steven Vermeulen*, 52, is appointed Executive Vice President in charge of the Telecom & Data Business Group and continues to supervise the North America area. He is from Belgium, based in Toronto, Canada. Steven Vermeulen joined Nexans in January 2016 after serving as Vice President & Managing Director Engineered Solutions within the Composite Division of Owens Corning, where he also held various positions in the United States and in Europe.
· *Five Corporate VPs in charge of support functions*
· *Nino Cusimano*, 54, Senior Corporate Vice President, General Counsel & Secretary General joined the Group in September 2018. He is based in Paris. Prior to joining Nexans, Nino Cusimano, Italian, was Group General Counsel for Telecom Italia and more recently, for CMA CGM. In addition, he has held senior global roles with multinational groups such as General Electric and PPG Industries
· *Juan Ignacio Eyzaguirre*, 35, Corporate Vice President, Strategy and Mergers & Acquisitions. Native from Chile, he is based in Paris. Prior to joining Nexans in February 2017, Juan Ignacio Eyzaguirre held various positions in the investment management sector, investment banking and at the office of the President of Chile.
· *Jérôme Fournier*, 49, will be appointed Corporate Vice President Innovation, Services & Growth on January 1^st 2019, replacing Dirk Steinbrink who has left the Group. Jérôme Fournier joined Alcatel Cables in 1997 in the metallurgy division. Between 2007 and 2011, he was in charge of R&D at Nexans. From 2011 to 2018, Jérôme Fournier worked for the Michelin Group where he held various positions as R&D Director. He will be based in Lyon, France.
· *Jean-Christophe Juillard*, 51, will join the Group on January 7, 2019 as Senior Corporate Vice President and Chief Financial Officer in charge of the Finance and Information Systems. He has more than 25 years of experience in finance in the United States and Europe, in various companies in manufacturing and energy sectors. Jean-Christophe Juillard began his career in New York with a subsidiary of Spie Batignolles and then worked in the audit department at Ernst & Young in Paris. He joined Alstom Transport in New York in 2004 as Vice President Finance for North and South America before being appointed Senior Vice President Finance of Alstom's Renewable Energy Division in 2011. Since 2013, he has been Executive Vice President and Chief Financial Officer of ContourGlobal Group, an American energy company successfully listed on the London Stock Exchange in 2017.
· Nicolas Badré will remain within the Group to ensure the transition with Jean-Christophe Juillard until the end of February 2019.
· *A new Senior Corporate Vice President Human Resources* based in Paris is currently being recruited to replace Anne-Marie Cambourieu who will leave the Group end of February 2019.
· *Pascal Portevin*, Deputy CEO, based in Paris, will take a role of special advisor and will continue to bring his experience and advice to the CEO and the Executive Committee. He will be in charge of strategic projects for the Group.
"This renewed management team is built to lead the implementation of the new industrial project that aims to redesign the Group's business model and introduce a new customer-centric corporate culture, based on a profound transformation of Nexans' activities towards services," said *Christopher Guérin, CEO of Nexans*. "I am confident that the individual expertise and leadership qualities of each member of this Executive Committee will help Nexans drive this change and gain a considerable competitive edge in the next three years."
In line with the implementation of this new Executive Committee, Nexans also announces the following appointments:
· Edeltraud Fabianke, as Corporate Vice President of Information Systems and Digital Transformation, reporting to the Group's Chief Financial Officer. Edeltraud, 42, is American and was previously President of the US-based Nexans Autoelectric of America (aeA).
· Jean-Marc Réty, as Director of the SHIFT Transformation Program, reporting directly to the CEO, in addition to his role of Corporate Vice President Purchasing since April 2014 when he joined Nexans. Jean-Marc Réty is Franco-American, 47 years old, and is based in Paris. Before joining Nexans, he held various functions as VP Procurement Group within Alstom Grid.
· Franck Blanchard, as Risk Management Director, reporting to the Senior Corporate Vice President, General Counsel & Secretary General. Franck Blanchard is 51 years-old, French and is based in Paris. He joined Nexans in 2008 and served as Deputy Chief Legal Officer of the Group.
As a global leader in advanced cabling and connectivity solutions, Nexans brings energy to life through an extensive range of best-in-class products and innovative services. For over 120 years, innovation has been the company's hallmark, enabling Nexans to drive a safer, smarter and more efficient future together with its customers.
Today, the Nexans Group is committed to facilitating energy transition and supporting the exponential growth of data by empowering its customers in four main business areas: Building & Territories (including utilities, smart grids, emobility), High Voltage & Projects (covering offshore wind farms, submarine interconnections, land high voltage), Telecom & Data (covering data transmission, telecom networks, hyperscale data centers, LAN), and Industry & Solutions (including renewables, transportation, Oil & Gas, automation, and others).
Corporate Social Responsibility is a guiding principle of Nexans' business activities and internal practices. In 2013 Nexans became the first cable provider to create a Foundation supporting sustainable initiatives bringing access to energy to disadvantaged communities worldwide. The Group's commitment to developing ethical, sustainable and high-quality cables drives its active involvement within several leading industry associations, including Europacable, the National Electrical Manufacturers Association (NEMA), International Cablemakers Federation (ICF) or CIGRE to mention a few.
Nexans employs more than 26,000 people with industrial footprint in 34 countries and commercial activities worldwide. In 2017, the Group generated 6.4 billion euros in sales. Nexans is listed on Euronext Paris, compartment A.
For more information, please visit: www.nexans.com & follow us on:
*Corporate Communication* *Investor relations*
Tel: +33 (0)1 78 15 04 78
Tel: +33 (0)1 78 15 05 41
Tel: +33 (0)1 78 15 04 67
email@example.com Marieme Diop
Tel: +33 (0)1 78 15 05 40
· 1811 29_Nexans Executive Committee_GB.pdf Reported by GlobeNewswire 3 hours ago.
Germany's economy minister dismissed on Thursday suggestions that his country's commitment to a pipeline - that will allow Russia to bypass Ukraine in pumping gas to Europe - undermines efforts to a de-escalate a crisis between the two neighbours.
Reported by Reuters India 3 hours ago.
Innovation in financial services and the application of new technologies dominated conversation on d...
Reported by Finextra 3 hours ago.
LONDON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) and fruquintinib in combination with checkpoint inhibitors. It is an important part of Chi-Med's strategy to explore the potential synergies of its drug candidates in combination with other anti-cancer treatments. These four new immunotherapy collaborations add to our ongoing studies combining savolitinib, Chi-Med’s highly selective c-Met inhibitor, with AstraZeneca PLC’s checkpoint inhibitor, durvalumab (Imfinzi^®).Today, Chi-Med is announcing the first steps to develop its vascular endothelial growth factor receptor (“VEGFR”) inhibitors, surufatinib and fruquintinib, in combination with various programmed cell death protein-1 (“PD-1”) monoclonal antibodies in several solid tumor settings:
· A global collaboration to evaluate the combination of surufatinib with toripalimab (JS001), a PD-1 monoclonal antibody being developed by Shanghai Junshi Biosciences Co. Ltd.;· A global collaboration to evaluate the combination of fruquintinib with sintilimab (IBI308), a PD-1 monoclonal antibody being developed by Innovent Biologics (Suzhou) Co. Ltd.;· A collaboration in China to evaluate the combination of surufatinib with HX008, a PD-1 monoclonal antibody being developed by Taizhou Hanzhong Pharmaceuticals, Inc.; and· A collaboration in China to evaluate the combination of fruquintinib with genolimzumab (GB226), a PD-1 monoclonal antibody being developed by Genor Biopharma Co. Ltd.
The global market for angiogenesis inhibitors was over US$18 billion in 2017, based on their use in around 30 different tumor settings. Each of the agreements announced today will pursue different initial indications within the field of solid tumors.
“Recent innovations in solid tumor drugs have focused on targeted therapies and immunotherapies which, as monotherapies, have both provided improved patients outcomes,” said Christian Hogg, Chief Executive Officer of Chi-Med. “We believe that the future of oncology treatments increasingly lies in combining therapies, utilizing multiple mechanisms of action (“MOA”) to confront tumors. Our unique next-generation anti-angiogenesis VEGFR inhibitors, with high selectivity and tolerability, make them ideal candidates for such combinations with immunotherapy agents such as PD-1/L1 monoclonal antibodies to prolong and expand the benefits of these therapies to more patients.”
Chi-Med’s proof-of-concept studies have already demonstrated the benefits of combinations with other kinase inhibitors or with chemotherapy.
Surufatinib (HMPL-012 or sulfatinib) is a novel, oral angio-immuno kinase inhibitor that inhibits VEGFR and fibroblast growth factor receptor (FGFR) which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R) which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. This dual angiogenesis-checkpoint inhibitor’s MOA may be very suitable for combination use with other immunotherapies. Surufatinib, as a monotherapy, is in late-stage clinical trials in China and began proof-of-concept clinical trials in the United States in July 2018.
Fruquintinib is a highly selective and potent oral inhibitor of VEGFR. Its unique kinase selectivity has been shown to reduce off-target toxicity thereby allowing possible use in combination with other agents. It was first approved for colorectal cancer in China in September 2018. It is in several late-stage clinical trials for lung and gastric cancer, including in combination with chemotherapy such as paclitaxel (Taxol^®) and other kinase inhibitors such as gefitinib (Iressa^®), and is in a Phase I clinical trial in the United States.
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med’s current expectations regarding future events, including its expectations for the clinical development of surufatinib and fruquintinib including as combination therapy with toripalimab, sintilimab, HX008 or genolimzumab; plans to initiate clinical studies for surufatinib and fruquintinib including as a combination therapy with toripalimab, sintilimab, HX008 or genolimzumab; its expectations as to whether such studies would meet their primary or secondary endpoints; and its expectations as to the timing of the enrollment completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of surufatinib and fruquintinib including as a combination therapy with toripalimab, sintilimab, HX008 or genolimzumab to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions, to gain commercial acceptance after obtaining regulatory approval, the potential market of surufatinib and fruquintinib including as a combination therapy with toripalimab, sintilimab, HX008 or genolimzumab for a targeted indication and the sufficiency of funding. In particular, as certain studies rely on the use of toripalimab, sintilimab, HX008 or genolimzumab as a combination therapeutic with surufatinib and fruquintinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and regulatory approval of toripalimab, sintilimab, HX008 or genolimzumab. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
***Media Enquiries*** ** **
**UK & Europe **– Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
**Americas** – Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
**Hong Kong & Asia ex-China** – Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
** ** – Zhou Yi, Brunswick +852 9783 6894 (Mobile)
**Mainland China** – Sam Shen, Edelman +86 136 7179 1029 (Mobile)
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited +44 (20) 7886 2500 Reported by GlobeNewswire 3 hours ago.
*29 November 2018*
*Acron’s IFRS EBITDA up 12% to USD 415 mn for 9M 2018, EBITDA margin reaches 33%*
Today Acron (Moscow Exchange and LSE: AKRN) released its consolidated IFRS financial statements for 9M 2018.
· Revenue was RUB 77,779 million, up 12% year-on-year (9M 2017: RUB 69,289 million). In dollar equivalent, revenue was up 7% to USD 1,266 million from USD 1,188 million.
· EBITDA* was up 18% year-on-year to RUB 25,486 million (9M 2017: RUB 21,620 million). In dollar equivalent, EBITDA was up 12% to USD 415 million from USD 371 million.
· EBITDA margin was 33%, against 31% year-on-year.
· Net profit was RUB 7,366 million (USD 120 million), down 27% year-on-year (9M 2017: RUB 10,135 million) because of a number of one-off events: a net exchange loss of RUB 4,608 million due to a revaluation of assets, loans and liabilities, and a RUB 1,890 million loss on derivatives.
· Net debt was up 4% to RUB 74,105 million, against RUB 71,123 million as of 30 June 2018. In dollar equivalent, net debt remained essentially unchanged at USD 1,130 million.
· Net debt/LTM EBITDA** was 2.2, against 2.3 as of 30 June 2018. In dollar equivalent, the ratio was 2.0, down from 2.2.
· Output of key products was 5,628,000 tonnes, up 3% year-on-year.
· Sales of key products totalled 5,447,000 tonnes, almost unchanged year-on-year.
*Alexander Popov, Chair of Acron’s Board of Directors, commented on the results:*
“Acron Group’s financials are steadily growing and demonstrate the sustainability of Acron Group’s business model. Over 9M 2018, EBITDA increased 12% year-on-year to USD 415 million. EBITDA margin reached 33%. The decrease in net profit is not representative, as it was due to one-time factors. We are securely in control of our debt burden. Net debt/LTM EBITDA in dollar equivalent was down to 2.0.
“With higher output, positive conditions on the mineral fertiliser market and the commissioning of a new urea unit, we expect Q4 financials to hit a record high.
“After considering Acron Group’s operating results and given the current debt burden, in 2018 the Board of Directors recommended three times that the general meeting resolve to pay dividends totalling RUB 337 per share. Next year, we also plan to pay dividends three times, which is in line with the best global practices and our shareholders’ interests”.
*Notes on Key Items in the Financial Statements*
The Group posted 9M 2018 revenue of RUB 77,779 million, up 12% year-on-year. This growth was due to higher global dollar prices for the Group’s products and another 5% increase in the average rouble-dollar exchange rate. Sales of key products in the reporting period were almost equal to 9M 2017 results.
Average Indicative Prices, USD/t, FOB Baltics/Black Sea
9M 2018 9M 2017 Change
NPK 16-16-16 295 263 +12.2 %
Ammonium nitrate 189 185 +2.2 %
UAN 163 140 +16.6 %
Urea 237 211 +12.5 %
Ammonia 273 262 +4.3 %
In the reporting period, the cost of sales was up 9% to RUB 41,024 million. Higher costs were mainly due to increased global prices for potash purchased for NPK production and growing depreciation. Depreciation went up after the launch of underground mining at the Oleniy Ruchey mine and the commissioning of a railway branch from the mine site to Titan station in late 2017.
Selling, general and administrative expenses were up 17% to RUB 5,983 million, mainly due to higher labour costs, Acron Group’s busier international activity and related expenses. Acron Group has continued to win markets in Latin America and Europe. In the reporting period, the Group started sales through its new trading company, Acron France SAS, and in the short term it expects to see marketing through subsidiaries in Argentina and Brazil.
Transportation expenses were up 17% to RUB 12,069 million due to the indexation of railway tariffs in Russia and higher lease rates for railcars.
EBITDA was up 18% to RUB 25,486 million. The Group posted EBITDA margin of 33% for the reporting period, up from 31% year-on-year. Veliky Novgorod-based Acron, Dorogobuzh and NWPC operated at margins of 34%, 29% and 28%, respectively.
Based on 9M 2018 results, the Group posted a net exchange loss of RUB 4,608 million due to a revaluation of assets, loans and liabilities (9M 2017: RUB 14 million loss). The Group also incurred a RUB 1,890 million loss on derivatives against a RUB 197 million profit for 9M 2017. These factors weighed down net profit 27% to RUB 7,366 million. However, it is worth noting that these factors were one-time in nature.
In 9M 2018, net operating cash flow was up 33% to RUB 17,812 million (9M 2017: RUB 13,375 million) due to the increased operating profit. Working capital was up RUB 1,796 million (up RUB 1,854 million in 9M 2017), mainly due to increased inventory before the high season.
Net cash spent on investments in the reporting period was RUB 9,089 million against RUB 8,031 million in 9M 2017. Capital expenditures were up 13% year-on-year to RUB 9,204 million (9M 2017: RUB 8,181 million).
Net cash spent on financing activities in 9M 2018 was RUB 11,011 million against RUB 13,034 million in 9M 2017. In the reporting period, Acron spent RUB 11,700 million to pay shareholder dividends (9M 2017: RUB 3,782 million). In the reporting period, the Group compensated Sberbank Investments for accumulated yield from holding a 19.9% stake in VPC by exercising the option to sell this stake and selling it back to Sberbank Investments. The compensation to Sberbank Investments was RUB 5,162 million. Net proceeds from borrowings in the reporting period were RUB 6,550 million, compared with RUB 6,662 of net repayment of borrowings in 9M 2017.
Total debt was down 4% from 30 June 2018 to RUB 87,457 million. In dollar equivalent, debt was down 8% to USD 1,333 million. Long-term debt made up 78% of total debt as of the end of the reporting period. Net debt was up 4% from 30 June 2018 to RUB 74,105 million. In dollar equivalent, net debt remained essentially unchanged at USD 1,130 million. Net debt/LTM EBITDA was 2.2 as of the end of the reporting period, down from 2.3 as of 30 June 2018. In dollar equivalent, the ratio decreased to 2.0 from 2.2.
Since June, urea prices have steadily grown on the back of strong demand in Latin America and India and short supply on the global market due to reduced Chinese exports, which plummeted 63% year-on-year over the first nine months of 2018, falling to 1.4 million tonnes from 3.7 million tonnes. Hamstrung by the high price of coal, which is a key feedstock for urea production in China, as well as by government environmental restrictions, Chinese producers are forced to hold prices over USD 300 FOB China, shifting their focus to the domestic market. October saw prices over USD 300 FOB Baltic, hitting a three-year record high. Sector analysts expect urea prices to remain high until early next year due to the traditional high season, and average 2019 prices are anticipated to exceed 2018 levels.
Because urea is a benchmark for such nitrogen fertilisers as ammonium nitrate and UAN, higher urea prices triggered increase across these products, as well. Over 2018, NPK prices saw an upward dynamic sustained by price growth in all three market segments: nitrogen, phosphorous and potash. NPK’s premium over the core product basket has remained high.
*Average Indicative Prices, USD/t, FOB Baltic Sea/Black Sea*
Q3 2018 Q2 2018 Q3 2017 Q3 2018 /
Q2 2018 change Q3 2018 /
Q3 2017 change
NPK 16-16-16 308 291 262 +5.9 % +17.8 %
AN 213 166 184 +28.2 % +15.8 %
UAN 174 155 126 +12.5 % +37.5 %
Urea 263 225 205 +17.2 % +28.7 %
Ammonia 303 232 199 +31.1 % +52.7 %
*The full version of Acron Group’s financial statements is available at www.acron.ru/en*
Note: The exchange rate used for currency conversion was RUB 65.5906 to USD 1 as of 30 September 2018 and RUB 57.6002 to USD 1 as of 31 December 2017. The average exchange rate for the first nine months of 2018 was RUB 61.4358 to USD 1. The average exchange rate for the first nine months of 2017 was RUB 58.3344 to USD 1.
* EBITDA is calculated as operating profit adjusted for depreciation and amortisation, foreign exchange gain or loss on operating transactions, and other non-cash and extraordinary items.
** LTM EBITDA is EBITDA calculated for the past 12 months.
Public Relations Phone: +7 (495) 777-08-65 (ext. 5196)
Investor Relations Phone: +7 (495) 745-77-45 (ext. 5252)
Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It has a wholly owned transportation and logistics infrastructure, including three Baltic port terminals and distribution networks in Russia and China. Acron’s subsidiary, North Atlantic Potash Inc. (NAP), holds mining licenses for 13 parcels of the potassium salt deposit at Prairie Evaporite, Saskatchewan, Canada. Acron also holds a minority stake (19.8%) in Polish Grupa Azoty S.A., one of the largest chemical producers in Europe.
In 2017, the Group sold 7.3 million tonnes of various products to 65 countries, with Russia, Brazil, Europe and the United States as key markets.
In 2017, the Group posted consolidated IFRS revenue of RUB 94,342 million (USD 1,617 million) and net profit of RUB 14,260 million (USD 244 million). Acron’s shares are on the Level 1 quotation list of the Moscow Exchange and its global depositary receipts are traded at the London Stock Exchange (ticker AKRN). Acron employs approximately 11,000 people.
For more information about Acron Group, please visit www.acron.ru/en. Reported by GlobeNewswire 2 hours ago.
DGAP-News: Savannah Resources PLC / Key word(s): Miscellaneous
29.11.2018 / 09:01
The issuer is solely responsible for the content of this announcement.
*Mina do Barroso Lithium Project Team Expands*
Savannah Resources plc (AIM: SAV, FWB: SAV and SWB: SAV) ('Savannah') or the 'Company'), the AIM quoted resource development company, which is focused on becoming Europe's most significant producer of lithium spodumene concentrates from its Portuguese Mina do Barroso Project ('Mina do Barroso' 'MdB' or 'the Project'), is pleased to announce it has added a number of leading Portuguese and international consultancy groups to its team. Work on the Feasibility Study, which has been progressing well under the management of the Primero Group and Savannah's in-house team, will be supported with inputs from the additional consultancies.
Additional groups have also been appointed to advise on funding, community engagement and communications for the Project. All consultants have prior lithium industry and/or significant in-country experience. The team now comprises:
· Primero Group appointed in July 2018 as the primary engineering group and lead manager for the Feasibility Study
· Knight Piésold appointed to lead on Geotechnical and Hydrological Engineering
· Quadrante appointed to consult on the Project's product transport and logistics requirements
· Nagrom continues to provide assay and metallurgical test work services
· ALS continues to provide assay and metallurgical test work services
· VISA Consultores is continuing its work on the Environmental Impact Statement Assessment
· CV&A Consultores, one of Portugal's most respected communications firms, has been appointed
· S317 Consulting appointed to develop a Stakeholder Management strategy, design a community engagement plan and source EU funding
· Noah's Rule appointed as funding adviser
*Savannah's CEO, David Archer said: *"We have built a high calibre team which speaks to the Mina do Barroso project's significance and the role it can play in providing the raw materials to underpin Europe's de-carbonisation polices and the development of the electric mobility industry in Europe.
"Savannah has assembled a group of consultants which offer an excellent combination of technical capability with highly relevant sector and country experience. Under the leadership of Primero and our in-house team work on the Feasibility Study is progressing well and we look forward to announcing key programme milestones on the way to completion of the Study next year as we look to become Europe's most significant producer of spodumene lithium concentrates.''
To view the press release with the illustrative maps and diagrams please use the following link:
For further information please visit www.savannahresources.com or contact:
David Archer Savannah Resources plc Tel: +44 20 7117 2489
David Hignell / Dugald J. Carlean (Nominated Adviser) Northland Capital Partners Ltd Tel: +44 20 3861 6625
Christopher Raggett / Camille Gochez (Broker) finnCap Ltd Tel: +44 20 7220 0500
Grant Barker (Equity Adviser) Whitman Howard Tel: +44 020 7659 1225
Charlotte Page / Lottie Wadham (Financial PR) St Brides Partners Ltd Tel: +44 20 7236 1177
Savannah is a diversified resources group (AIM: SAV) with a portfolio of energy metals projects - lithium in Portugal and copper in Oman - together with the world-class Mutamba Heavy Mineral Sands Project in Mozambique, which is being developed in a consortium with the global major Rio Tinto. The Board is committed to serving the interests of its shareholders and to delivering outcomes that will improve the lives of our staff and the communities we work with.
The Company is listed and regulated on AIM and the Company's ordinary shares are also available on the Quotation Board of the Frankfurt Stock Exchange (FWB) under the symbol FWB: SAV, and the Börse Stuttgart (SWB) under the ticker "SAV".
29.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de -------------------- Reported by EQS Group 3 hours ago.
Reports claim Newcastle’s Freddie Woodman is wanted by Leeds United, and fans on Tyneside are absolutely loving the idea.
Reported by Football FanCast 2 hours ago.
*WisdomTree Issuer plc – Daily Fund Prices * *28-November-18*
* * * *
Fund Dealing Date ISIN Code Shares Base Net Assets NAV/Share
in Issue Currency
WisdomTree AT1 CoCo Bond UCITS ETF – USD 28/11/2018 IE00BZ0XVF52 268045 USD 24,897,354.39 92.885
WisdomTree AT1 CoCo Bond UCITS ETF – EUR Hedged 28/11/2018 IE00BFNNN236 20828 EUR 2,024,270.58 97.1899
WisdomTree AT1 CoCo Bond UCITS ETF – GBP Hedged 28/11/2018 IE00BFNNN459 20740 GBP 2,023,618.60 97.5708
WisdomTree AT1 CoCo Bond UCITS ETF – USD Acc 28/11/2018 IE00BZ0XVG69 9000 USD 839,694.78 93.2994
WisdomTree AT1 CoCo Bond UCITS ETF – USD Hedged 28/11/2018 IE00BFNNN012 20962 USD 2,054,138.05 97.9934
WisdomTree CBOE S&P 500 PutWrite UCITS ETF - USD Acc 28/11/2018 IE00BD49R243 1680000 USD 83,914,151.35 49.9489
WisdomTree Emerging Asia Equity Income UCITS ETF 28/11/2018 IE00BYPGT035 1125000 USD 12,069,388.00 10.7283
WisdomTree Emerging Markets Equity Income UCITS ETF 28/11/2018 IE00BQQ3Q067 1917097 USD 28,601,773.25 14.9193
WisdomTree Emerging Markets Equity Income UCITS ETF Acc 28/11/2018 IE00BDF12W49 108242 USD 2,041,083.39 18.8567
WisdomTree Emerging Markets Small Cap Dividend UCITS ETF 28/11/2018 IE00BQZJBM26 1375000 USD 22,125,172.50 16.091
WisdomTree Enhanced Commodity UCITS ETF – EUR Hedged Acc 28/11/2018 IE00BG88WG77 25000 EUR 238,196.18 9.5278
WisdomTree Enhanced Commodity UCITS ETF – GBP Hedged Acc 28/11/2018 IE00BG88WH84 1425000 GBP 13,627,590.32 9.5632
WisdomTree Enhanced Commodity UCITS ETF - USD 28/11/2018 IE00BZ1GHD37 525000 USD 5,291,018.05 10.0781
WisdomTree Enhanced Commodity UCITS ETF - USD Acc 28/11/2018 IE00BYMLZY74 23650000 USD 239,389,839.66 10.1222
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR 28/11/2018 IE00BD49R912 30000 EUR 1,479,598.22 49.3199
WisdomTree EUR Aggregate Bond Enhanced Yield UCITS ETF – EUR Acc 28/11/2018 IE00BD49RB39 30000 EUR 1,479,599.37 49.32
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF 28/11/2018 IE00BD49RJ15 30000 EUR 1,482,803.63 49.4268
WisdomTree EUR Government Bond Enhanced Yield UCITS ETF – EUR Acc 28/11/2018 IE00BD49RK20 30000 EUR 1,482,804.10 49.4268
WisdomTree Europe Equity Income UCITS ETF 28/11/2018 IE00BQZJBX31 3633600 EUR 45,270,266.19 12.4588
WisdomTree Europe Equity Income UCITS ETF Acc 28/11/2018 IE00BDF16007 40010 EUR 569,216.61 14.2269
WisdomTree Europe Equity UCITS ETF - CHF Hedged Acc 28/11/2018 IE00BYQCZT11 17096 CHF 265,520.63 15.5312
WisdomTree Europe Equity UCITS ETF - EUR Acc 28/11/2018 IE00BYQCZX56 604306 EUR 9,531,419.11 15.7725
WisdomTree Europe Equity UCITS ETF - GBP Hedged 28/11/2018 IE00BYQCZQ89 342454 GBP 3,547,827.91 10.36
WisdomTree Europe Equity UCITS ETF - USD Hedged 28/11/2018 IE00BVXBH163 3135804 USD 51,440,778.43 16.4043
WisdomTree Europe Equity UCITS ETF - USD Hedged Acc 28/11/2018 IE00BYQCZP72 3995137 USD 73,879,372.15 18.4923
WisdomTree Europe Small Cap Dividend UCITS ETF 28/11/2018 IE00BQZJC527 3440006 EUR 53,862,771.52 15.6578
WisdomTree Europe Small Cap Dividend UCITS ETF Acc 28/11/2018 IE00BDF16114 656066 EUR 8,912,748.47 13.5851
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR 28/11/2018 IE00BZ56SY76 416881 EUR 5,694,084.88 13.6588
WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc 28/11/2018 IE00BZ56TQ67 938013 EUR 14,154,578.65 15.09
WisdomTree Germany Equity UCITS ETF - CHF Hedged Acc 28/11/2018 IE00BYQCZ914 45884 CHF 776,450.73 16.922
WisdomTree Germany Equity UCITS ETF - EUR Acc 28/11/2018 IE00BYQCZC44 251123 EUR 3,783,198.35 15.0651
WisdomTree Germany Equity UCITS ETF - GBP Hedged 28/11/2018 IE00BVXBGY20 507894 GBP 4,797,325.26 9.4455
WisdomTree Germany Equity UCITS ETF - USD Hedged 28/11/2018 IE00BYQCZ682 17536 USD 294,895.48 16.8166
WisdomTree Global Quality Dividend Growth UCITS ETF - USD 28/11/2018 IE00BZ56RN96 63688 USD 1,265,346.95 19.8679
WisdomTree Global Quality Dividend Growth UCITS ETF - USD Acc 28/11/2018 IE00BZ56SW52 454761 USD 9,380,024.66 20.6263
WisdomTree India Quality UCITS ETF - USD 28/11/2018 IE00BDGSNK96 152500 USD 2,603,003.14 17.0689
WisdomTree India Quality UCITS ETF - USD Acc 28/11/2018 IE00BDGSNL04 222500 USD 3,806,271.75 17.1068
WisdomTree ISEQ 20 UCITS ETF 28/11/2018 IE00BVFB1H83 1300000 EUR 15,494,654.58 11.919
WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc 28/11/2018 IE00BYQCZL35 215945 CHF 3,892,802.74 18.0268
WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc 28/11/2018 IE00BYQCZJ13 825839 EUR 12,807,069.02 15.5079
WisdomTree Japan Equity UCITS ETF - GBP Hedged 28/11/2018 IE00BYQCZF74 113978 GBP 1,185,387.27 10.4001
WisdomTree Japan Equity UCITS ETF - JPY Acc 28/11/2018 IE00BYQCZN58 2333721 USD 42,729,177.18 18.3095
WisdomTree Japan Equity UCITS ETF - USD Hedged 28/11/2018 IE00BVXC4854 13268036 USD 208,597,963.14 15.7218
WisdomTree Japan Equity UCITS ETF - USD Hedged Acc 28/11/2018 IE00BYQCZD50 736932 USD 12,618,526.82 17.1231
WisdomTree Japan SmallCap Dividend UCITS ETF - USD 28/11/2018 IE00BFXYK923 20000 USD 938,027.35 46.9014
WisdomTree Japan SmallCap Dividend UCITS ETF - USD Acc 28/11/2018 IE00BFXYKD63 20000 USD 938,027.35 46.9014
WisdomTree UK Equity Income UCITS ETF 28/11/2018 IE00BYPGTJ26 840000 GBP 4,368,874.59 5.201
WisdomTree US Equity Income UCITS ETF 28/11/2018 IE00BQZJBQ63 1516315 USD 29,230,872.41 19.2776
WisdomTree US Equity Income UCITS ETF - EUR Hedged Acc 28/11/2018 IE00BD6RZW23 17573 EUR 289,133.52 16.4533
WisdomTree US Equity Income UCITS ETF - GBP Hedged Acc 28/11/2018 IE00BD6RZZ53 162189 GBP 2,398,603.09 14.7889
WisdomTree US Equity Income UCITS ETF Acc 28/11/2018 IE00BD6RZT93 274649 USD 5,214,272.99 18.9852
WisdomTree US Multifactor UCITS ETF – USD 28/11/2018 IE00BD8ZCY59 10000 USD 492,471.01 49.2471
WisdomTree US Multifactor UCITS ETF – USD Acc 28/11/2018 IE00BD8ZD313 10000 USD 492,471.05 49.2471
WisdomTree US Quality Dividend Growth UCITS ETF - USD 28/11/2018 IE00BZ56RD98 42491 USD 913,960.83 21.5095
WisdomTree US Quality Dividend Growth UCITS ETF - USD Acc 28/11/2018 IE00BZ56RG20 687537 USD 15,277,458.06 22.2206
WisdomTree US Small Cap Dividend UCITS ETF 28/11/2018 IE00BQZJBT94 650000 USD 12,831,739.59 19.7411 Reported by GlobeNewswire 2 hours ago.
Dublin, Nov. 29, 2018 (GLOBE NEWSWIRE) -- The "European Road Freight Transport 2018 - Market Report" report has been added to *ResearchAndMarkets.com's* offering.European Road Freight Transport 2018 provides analysis of how the market is changing by assessing cost structures, EU policy, shippers' requirements and Brexit.
It then takes a deep dive into the potential of digital freight marketplaces and autonomous vehicles and looks at the practical implementation of these technologies by LSPs.
Europe's road freight market has seen strong growth over the last two years, with nominal growth of 5.4% expected in 2018, an improvement over the 4.5% expansion seen in 2017. The market will obviously want to see this trend continue, but 2019 will be a crunch year as providers seek to integrate technology, deal with rising fuel costs, overcome the ongoing driver shortage and, of course, Brexit looms ever nearer on the horizon.Perhaps more than ever, what's needed is not only a keen awareness of changes in the market and the agility to react, but the ability to transform internally while also continuing to deliver against shippers' demands for price transparency and supply chain visibility throughout the challenges ahead.
The European road freight market is undergoing transformative changes, with digitisation promising to revolutionise traditional practices. Initiatives by tech start-ups and the biggest players in the market reinforce the need to constantly innovate to remain competitive, resulting in a two-speed market and a gap between the most advanced and the rest of the industry.Smaller and medium-size logistics companies must take advantage of technology and other opportunities to innovate services for shippers and compete successfully with the bigger players. Adding to this challenging scenario are customers changing expectations and demands for supply chain visibility and price transparency.
*European Road Freight Transport 2018 examines:*· Data for European domestic and international road freight market
· 2017 market sizes
· 5-year CAGR growth rates 2017-2022
· Brexit and EU Policy:
· Analysis of the effects deglobalisation trends (Brexit) and EU policy may have for the road freight sector
· Digital Freight Marketplaces:
· Analysis of the potential of digital freight marketplaces and autonomous vehicles and their impact on the market and carriers' margins
· Interviews with LSP's:
· Case studies on the implementation of different technologies among major LSPs supported by interview evidence
· Road Freight Provider Profiles:
· Profiles of major road freight providers - including strategies, finances, technologies used and their implementation
· European Country Profiles: country profiles for each leading European transport and logistics market, including measures of logistics performance, infrastructure quality, volumes, freight rates and market sizing data
*What will you discover?*
· How can road freight companies turn the pressures of technology into potential? What approaches are the leading road freight operators taking towards technology?
· How will digital freight marketplaces affect the road freight market and carriers' margins in future?
· What are the current market risks and how to deal with them?
· How large is the European domestic and international road freight market and how fast is it growing?
*Key Topics Covered:* *
1.0 Key Findings **2.0 Introduction *
*3.0 European Road Freight Market Fundamentals *
3.1 Key Findings
3.2 Market Structure
3.3. Current market risks by Tim Phillips, Director of Duma Consulting and former CEO of Freightex
3.4 European Road Freight Supply Side Issues and Trends
3.5 European Road Freight Demand Side Issues and Trends
3.6 Supply Chain Fragmentation
3.7 Vehicle Utilisation and Rates of Empty Running
3.8 Cost Structures
3.9 Freight Rates
3.10 The Relative Importance of Domestic and International Road Freight in Europe
3.11 The Nature of International Road Freight Transport
3.13 Additional Road Freight Data Segmentation
3.14 Current Shippers' Focus by Tim Phillips
3.15 Brexit - Short and Long Term Implications for the UK and European Road Freight Industry by John Manners-Bell, CEO of Transport Intelligence
3.15.1 Short Term Regulatory Imperatives
3.15.2 Border Controls and Ensuring Frictionless Trade
3.15.3 The Role of the Port of Dover
3.15.4 UK Government Advice
3.15.5 Brexit viewed from a supply chain perspective by Wolfgang Lehmacher, Head of Supply Chain and Transport Industries, World Economic Forum
3.16 EU Mobility Package: Where Are We Now?
3.17 Road Transport - The Way Forward
*4 Road Freight Innovation *
4.1 Key Findings
4.2 Logistics Innovations: Foreword
4.2.1 Digital Marketplaces in the Road Freight/Trucking Sector
4.2.2. Autonomous trucks
4.3 Innovation in Practice
220.127.116.11 DHL Freight
18.104.22.168 DB Schenker
22.214.171.124 Kuehne + Nagel
4.4. Conclusion by Tim Phillips
*5.0 Market Size And Forecasts *
5.1 Key Findings
5.2 Road Freight Market (2017)
5.3 Road Freight Market (2018)
5.4. Road Freight Market (2022)
5.5 Top 10 European Road Freight Transport Providers
5.6 Domestic Road Freight Market (2017)
5.7 Domestic Road Freight Market (2018)
5.8 Domestic Road Freight Market (2022)
5.9 International Road Freight Market (2017)
5.10 International Road Freight Market (2018)
5.11 International Road Freight Market (2022)
*6.0 Transport And Logistics Profiles Of European Countries *
6.1. Key Findings
6.2 Volume of Road Transport Market
6.3 Largest Domestic Road Freight Markets
6.4 Largest International Road Freight Markets
6.5 Top Country-To-Country International Road Freight Trade Lanes (m tkm)
6.6 European Road Freight Transport: Total Market Trip Distance by Weight Uplifted
6.7 Profiles of European Countries
*7.0 Road Freight Operator Profiles*· Dachser
· DB Schenker
· DHL Freight
· Kuehne + Nagel
· LKW Walter
· SNCF Logistics (Geodis)
For more information about this report visit https://www.researchandmarkets.com/research/xnccxn/european_road?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Logistics Reported by GlobeNewswire 2 hours ago.
We do the Group B maths so you don’t have to as Brendan Rodgers’ side attempt to march on in Europe.
Reported by Daily Record 2 hours ago.
REGTECH100 honours Jumio and its innovative Netverify® solution for enabling financial institutions to reliably verify their online customers, defend against fraud and meet growing compliance mandates
LONDON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Jumio, the leading AI-powered trusted identity as a service provider, today announced that it has been chosen as one of REGTECH100’s most innovative companies for the second consecutive year.A panel of analysts and industry experts chose winners from a list of 824 candidates from across the world, which is nearly double the number of companies considered last year, highlighting the rapid growth and competitive nature of the RegTech industry. FinTech Global, a London-based FinTech publication, is behind REGTECH100. The selected companies were recognised and commended for their innovative use of technology to generate efficiencies and performance enhancements across the compliance function with financial institutions.
“We are honoured to be recognised for the second consecutive year for our work as a world leader in online identity verification,” said Stephen Stuut, CEO of Jumio. “This is further validation of our continuous innovation in next-generation digital identity verification. It recognises the benefits of pioneering augmented intelligence, machine learning and deep learning algorithms to better identify fraudulent IDs and expedite the verification process.”
Jumio’s state-of-the-art Netverify enables businesses to reduce fraud and increase revenue while helping them to provide a fast, seamless customer experience. Jumio uses a combination of biometrics, computer vision, machine learning, AI and verification experts to verify ID credentials issued in 220 countries and territories and better protect the ecosystems of its business customers.
Leading organisations and companies including HSBC, Coinbase, Monzo and others in the financial services industry use Jumio’s solutions to enable them to verify their online users, detect fraudulent IDs, and meet compliance mandates. To learn more about Jumio and its award-winning solution, please visit: https://www.jumio.com/trusted-identity/netverify/.
When identity matters, trust Jumio. Jumio is the creator of Netverify which enables businesses to increase customer conversions while providing a seamless customer experience and reducing fraud. By combining the three core pillars of ID Verification, Identity Verification and Document Verification, businesses now have a complete solution that allows them to establish the real-world identity of the consumer.
Leveraging advanced technology including augmented AI, biometric facial recognition, machine learning and human review, Jumio helps organizations to meet regulatory compliance including KYC, AML and GDPR and definitively establish the digital identity of their customers. Jumio has verified more than 150 million identities issued by over 200 countries and territories from real time web and mobile transactions. Jumio’s solutions are used by leading companies in the financial services, sharing economy, cryptocurrency, retail, travel and online gaming sectors. Based in Palo Alto, California, Jumio operates globally with offices in the U.S., Europe and Asia Pacific and has been the recipient of numerous awards for innovation. For more information, please visit www.jumio.com.
The REGTECH100 is an annual list of 100 of the world’s most innovative RegTech companies. These are the companies every financial institution needs to know about as they consider and develop their mission critical RegTech and digital transformation strategies.
The 2018 REGTECH100 list received worldwide attention. Companies that won places on the list generated huge awareness among financial institutions. Many were approached directly by banks and other major FIs, while others got a more welcome reception from prospective clients, which has led to new partnerships, new investments and increased sales.
The list has been updated for 2019 in the fact of the new regulatory challenges financial institutions are facing. It will help senior management at compliance, technology and innovation divisions sort through all the suppliers and identity companies who are most likely to have a lasting impact on the industry.
*Europe Media Contact*
+44 (0) 7775 557578
*U.S. Media Contact*
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a47f5e4e-4e5b-48ed-b944-0dbfe93118e6 Reported by GlobeNewswire 2 hours ago.
· *The Institute of International Finance says austerity probably damages economies trying to recover from the great financial crisis. *
· *Since 2008, GDP growth in the US has been 10% greater than in Europe, the IIF says. In terms of GDP growth per capita, the reduction was 5%. Fiscal tightening in Europe was the main difference. *
· *Trend growth in the US was double what it was in Europe following the financial crisis, the IIF says. Prior to 2008, they had been the same.*
· *"Fiscal austerity is a mistake," IIF Managing Director & Chief Economist Robin Brooks tells Business Insider.*
Since the great financial crisis of 2008 there has been a debate about what the right plan for economic recovery should have been across the US and Europe.
For conservatives, fiscal "austerity" was the answer — limiting debt, deficits, and consequently government spending, in order to put the economy on a sound basis for future growth.
The left, by contrast, argued that fiscal spending was the solution — using the government to supply the investment money that disappeared in the private markets during the crash, thus priming the pump (but at the risk of funding it with more debt).
Now, the Institute of International Finance has published a series of research papers showing that austerity was probably the wrong choice. Fiscal tightening in Europe reduced GDP growth by 10% compared to the US, the IIF says. In terms of GDP growth per capita, the difference was 5%.
Trend growth in the US was double that of Europe following the financial crisis, the IIF says, whereas prior to 2008 they had been the same.
Austerity hurts growth, in other words.
The main difference between Europe and the US in the post-crisis period was that the US embarked on an era of robust government spending in addition to a massive monetary stimulus package from the US Federal Reserve.
The European Central Bank also adopted a monetary program of low interest rates and quantitative easing (QE). But the European Union continued to enforce its fiscal austerity program, banning member governments from running deficits greater than 3% of GDP. The EU also forced countries to pay down their debts during the recovery. The most dramatic example of that was Greece, which stayed inside the EU's debt repayment program even though its economy shrunk by 45%, peak to trough. Today, the EU is trying to force Italy to keep its deficit below 1.8% of GDP, even though the Italian economy has stalled at 0% growth.
*Two continents conducted an historic experiment in macroeconomics, and the data is stark*
The two continents thus conducted an historic experiment in macroeconomic policy: The US went on a government spending splurge while Europe tightened its purse strings.
The IIF's data is stark. Europe is now poorer than the US, in growth terms, because of austerity, according to Managing Director & Chief Economist Robin Brooks and Senior Research Analyst Greg Basile.
"What I find fascinating is that trend growth in the US and the eurozone was basically the same," Brooks told Business Insider. "Leading up to the global financial crisis, they were both growing around 2%. And afterwards you have this big divergence."
*"It's not like Europeans are fundamentally lazier than Americans in the last 10 years"*
"So to me, that says it's not like Europeans are fundamentally lazier than Americans in the last 10 years. It's just that [economic] policy hasn't been as supportive."
Brooks and Basile discovered the gap while researching the IMF's data on potential GDP output gaps. Put simply, economists like to compare current economic growth with a measure of "potential" economic growth in order to test whether an economy is functioning at its peak capacity or not.
They noticed an anomaly in the data that was particularly dramatic in a comparison of Italy and Australia. Australia, famously, has not had a recession since 1991 and escaped the great financial crisis relatively unscathed. Cumulatively it has added 30 percentage points of GDP growth since 2008. Italy, however, took a big hit in 2008 and has been mired in a debt crisis ever since. Its economy contracted by 4% since 2008. Yet according to the IMF data, both countries only had output gaps of just under zero, suggesting that both countries are functioning at near-full capacity. Brooks and Basile's research says.
*Read more: *Europe is faltering
On its face, that's weird: Australia's economy ought to be busting at the seams. And stagnant Italy ought to have plenty of unused economic "slack" sitting on the sidelines. But statistically, they are the same (in terms of how far they are from fulfilling their potential).
"It's just a completely counterintutive result, where the definition of the output gap runs counter to any economic common sense, basically," Brooks says. It's a similar picture for Spain and Greece. It's "devoid of economic intuition."
*If the IIF is right, then the ECB might be about to make an historic mistake*
The poor performance of Europe vs America is further disguised by Europe's current account surplus. The surplus is the excess of exports Europe produces compared to imports. A surplus suggests Europe is selling more things to foreigners than it is buying from them. Economists usually regard this as a sign of health. Germany's historic manufacturing strength is the usual explanation for Europe's rosy export surplus.
But Brooks and Basile say Europe's glass is actually only half full. There's a trade surplus because domestic demand outside Germany is so weak, lowering imports. If you factor in a more realistic output gap, then Europe's current account would be in deficit, they say.
The trade stuff is highly technical, to be sure. But if the IIF is right, then the ECB might be about to make an historic mistake. It is currently in the process of "normalizing" its monetary policy, by bringing QE to an end and raising interest rates. Brooks and Basile argue that the trade data and the mismeasured output gap show that eurozone economic activity is much weaker than the bank presumes, and deflationary pressure is much stronger. Conditions suggest the ECB needs to continue to help the economy with loose monetary policy, not end it; and the euro is overvalued vs the dollar, and thus ought not to be strengthened via tighter monetary policy.
*Read more*: Britain enters the 'Greek fallacy' phase of Brexit
*Solid data show that austerity in response to a recession makes both countries and people poorer*
For ordinary people, the bottom line is that there is now solid data to show that austerity in response to a recession makes both countries and people poorer than they need to be.
This also helps explain why many European countries continue to have persistently high unemployment rates — Italy's is more than double the US or the UK — even though the stats say the output gap is small, the IIF's data suggests.
Persistent unemployment also generates a phenomenon called "hysteresis." It means that when people are out of work for a long time, they lose the skills they need to rejoin the workforce. The economy is then prevented from growing faster when conditions improve because employers cannot find the workers they need, even though there are plenty of people out of work. Austerity inflicts damage on the total economy, in other words.
"I think the main message as I see it is, ECB normalisation is a mistake," Brooks says. "Fiscal austerity is a mistake."
*SEE ALSO: The 'zombie' problem: Low interest rates and 'leveraged loans' sustain a vast number of lousy companies which should have gone to the wall years ago*
Join the conversation about this story »
NOW WATCH: Trump once won a lawsuit against the NFL — but the result was an embarrassment Reported by Business Insider 1 hour ago.
While policymakers craft a new long-term European Union framework for the energy transition, some of the most intense changes will fall to local utilities in Europe's cities. For some cities, their own preparations closely track what the European Commission is envisioning.
Reported by EurActiv 2 hours ago.
Greg Gibbs, Analyst at Amplifying Global FX Capital, suggests that for much of this year, the US economy and asset markets appeared impervious to global market upheaval but in recent months, US asset markets, from stock markets to credit spreads, are experiencing negative feedback from fears on the global economy.
“The US economy may remain robust. However, its big high tech companies are facing headwinds, the US fiscal impulse may be near a peak, negative feedback concerned with its protectionist trade policy may increase, and the fall in oil prices may dampen the now significant US energy sector.”
“Having raised interest rates significantly over the last few years, the USA now has more space to ease policy if the global economy deteriorates and undermines the US economy. This can make the USD more responsive to global economic conditions than other currencies.”
“It may not come to rate cuts in the US in the year ahead, but headwinds may soon pick up enough for the Fed to pause on further rate hikes for an extended period. This could be enough to turn sentiment for the USD.”
“Although in light of the widening US fiscal and trade deficit a divided Congress and a combative President who is facing the Mueller probe, threatening to shut down government over border wall funding, threatening trade disputes with China and Europe, and openly criticising Fed rates policy – a levelling off in US GDP growth could be enough to turn global investor sentiment against the USD.” Reported by FXstreet.com 1 hour ago.
Aspo Plc / Telko Ltd
28.11.2018 at 11.30
Aspo's Telko Ltd has acquired business of Danish company H H plastkombi a/s Telko Ltd and H H plastkombi a/s have signed on the 19th of November an agreement by which Telko Ltd will acquire whole business of H H plastkombi.
H H plastkombi a/s is over 28 years old Danish company headquartered in Helsinge, Denmark. Business of H H plastkombi a/s includes distribution of engineering plastics, masterbatches and BOY injection molding machines in Denmark, as well as selling of range of accessories to the plastics industry. Sales revenue of H H plastkombi a/s is approximately 3 MEUR.
Telko Ltd is an Espoo, Finland, headquartered international plastics, chemicals and lubricants expert and distribution company with over 300 employees, sales of over 260 MEUR and history of 110 years. Telko is a leading plastics distribution company on its markets representing world leading brands.
Closing of the transaction is estimated to take place on the 2nd of January, 2019. Until then the both companies continue to operate independently serving each of their own customers.
"We are sure, that by doing this investment, we are able to serve plastics industry even better", says Kalle Kettunen, CEO of Telko.
Telko Ltd is owned by Aspo Plc, which was founded in 1929.
For more information:
Kalle Kettunen, Telko Ltd, CEO, tel. +358 40 558 5478, firstname.lastname@example.orgTelko Ltd is a Finland based leading distributor and expert of raw materials (plastics, chemicals, lubricants) having daughter companies in 16 countries and representing leading principals of the industries. The Company operates locally in the Nordic countries, Baltics, Russia, Ukraine, Poland and in many other growing markets in Eastern part of the world. Telko's extensive customer service includes also tailor-made technical support and development of production processes together with customers. Company's strength is comprehensive knowledge of raw materials, which knowledge Telko's specialists have got during the years while working with holistic customer projects. Telko has also a terminal in Rauma and many local warehouses in different markets where the company operates. www.telko.com Aspo Plc is a conglomerate that owns and develops business operations in Northern Europe and growth markets focusing on demanding B-to-B customers. Our strong company brands - ESL Shipping, Leipurin, Telko and Kauko - aim to be the market leaders in their sectors. They are responsible for their own operations, customer relationships and the development of these. Together they generate Aspo's goodwill. Aspo's Group structure and business operations are continually developed without any predefined schedules. www.aspo.com Reported by GlobeNewswire 1 hour ago.
U.S. carmaker Ford, Britain's biggest automotive engine builder, warned that a no-deal Brexit would be a "catastrophe" and that the agreement between London and Brussels should be approved.
Reported by Reuters India 38 minutes ago.